Literature DB >> 19112766

Refractory dissecting cellulitis of the scalp treated with adalimumab.

Smita V Sukhatme1, Yolanda M Lenzy, Alice B Gottlieb.   

Abstract

Dissecting cellulitis of the scalp (DCS) is a suppurative, neutrophillic dermatosis. Therapies typically provide short-term improvement and include antibiotics, prednisone, and isotretinoin, as well as radiation, surgical excision, and laser ablation. The authors report the use of the tumor necrosis factor (TNF) blocker, adalimumab, to successfully treat a 39-year-old male with a long-standing history of DCS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19112766

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

Review 1.  Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases.

Authors:  Debbie T Lim; Neena M James; Sobia Hassan; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

2.  Recalcitrant Dissecting Cellulitis of the Scalp Treated Successfully with Adalimumab with Hair Regrowth: A Case Report.

Authors:  Adel Alsantali; Basel Almalki; Abdullah Alharbi
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-05-10

3.  Dissecting cellulitis (DSC) after interferon beta-1a treatment and scalp trauma.

Authors:  Jeff Donovan
Journal:  JAAD Case Rep       Date:  2015-08-25

4.  Surgical Management and Reconstruction of Hoffman's Disease (Dissecting Cellulitis of the Scalp).

Authors:  Justin M Hintze; Brittany E Howard; Carrlene B Donald; Richard E Hayden
Journal:  Case Rep Surg       Date:  2016-02-07

5.  Surgical management of dissecting cellulitis of the scalp using free latissimus dorsi flap and meshed split-thickness skin graft: A case report.

Authors:  Nicoleta-Sara Baneu; Vlad Adam Bloancă; Diana Szilagyi; Patricia Cristodor; Alexandru Pesecan; Tiberiu Ioan Bratu; Zorin Petrişor Crăiniceanu
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.